Biodexa Pharmaceuticals Valuation
Is 5MP1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 5MP1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 5MP1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 5MP1's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 5MP1?
Key metric: As 5MP1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 5MP1's PS Ratio? | |
|---|---|
| PS Ratio | 26.8x |
| Sales | UK£83.00k |
| Market Cap | UK£2.22m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 5MP1's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
BPXA Bellicum Pharmaceuticals | 0.5x | n/a | €772.4k |
CNW co.don | 0.7x | n/a | €6.5m |
MDG1 Medigene | 3.3x | 16.1% | €24.9m |
ECX Epigenomics | 6.6x | n/a | €980.2k |
5MP1 Biodexa Pharmaceuticals | 26.8x | -70.6% | €2.8m |
Price-To-Sales vs Peers: 5MP1 is expensive based on its Price-To-Sales Ratio (26.8x) compared to the peer average (3.5x).
Price to Sales Ratio vs Industry
How does 5MP1's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 5MP1 is expensive based on its Price-To-Sales Ratio (26.8x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is 5MP1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 26.8x |
| Fair PS Ratio | 0.1x |
Price-To-Sales vs Fair Ratio: 5MP1 is expensive based on its Price-To-Sales Ratio (26.8x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.46
7D
-3.4%
1Y
2.1%
Pharming Group
€498.9m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
-1.0%
1Y
-32.7%
Merck
US$249.2b
Operates as a healthcare company worldwide.
6MK
US$93.10
7D
-1.0%
1Y
-0.1%